ARMO BioSciences Announces Promising Response Rates and Survival Data in Patients with Advanced NSCLC and RCC from Phase 1/1b Trial for Immunotherapy AM0010 with Checkpoint Inhibitors

posted in: News | 0

ARMO BioSciences, Inc., a late-stage immuno-oncology  company, today announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) in combination with immune checkpoint inhibitors for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (RCC). These data are being presented in poster sessions during the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago, Illinois. Five poster presentations with clinical data on AM0010 are being presented at the 2017 ASCO Annual Meeting. AM0010 immunotherapy is being evaluated in an ongoing Phase 1/1b clinical trial that has enrolled 352 advanced cancer patients.

“As we continue to treat and follow up patients for longer durations in the Phase 1/1b clinical trial of our immunotherapy AM0010, we are very encouraged by the response rates, survival indicators, and safety profile we are observing in patients with different types of advanced cancer,” said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO BioSciences.  “In advanced NSCLC and metastatic RCC, the combination of our immunotherapy AM0010 with either of the checkpoint inhibitors nivolumab or pembrolizumab induced high response rates and durable objective responses. It is particularly promising to see these high response rates in advanced NSCLC patients, even those with low PD-L1 expression, who have the highest unmet medical need. In this ongoing Phase 1/1b clinical trial, we look forward to continuing to monitor the survival of these patients living with advanced NSCLC and RCC and we are excited by the very promising trends seen to date in these difficult-to-treat types of cancers.”

Press Release